Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
NCT ID NCT06738303
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This trial compares two treatment approaches for men with aggressive, metastatic prostate cancer that has stopped responding to hormone therapy and docetaxel. One approach uses a combination of two chemotherapy drugs (cabazitaxel and carboplatin), while the other uses a radioactive drug (Lu-PSMA-617) that targets a protein on prostate cancer cells. The study will measure how well each treatment lowers PSA levels and delays cancer progression, aiming to identify which option works better for this difficult-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of two chemotherapy drugs (cabazitaxel and carboplatin) given intravenously, compared with a radioactive drug (Lu-PSMA-617, also known as Pluvicto) that targets prostate cancer cells.
- What this could lead to
- If one treatment proves more effective, it could offer a new standard option for men with aggressive prostate cancer that has stopped responding to current therapies.
- What could go wrong
- This is a small, phase 2 trial, so results may not be definitive. Both treatments have significant side effects, and the comparison may not show a clear winner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?